285 related articles for article (PubMed ID: 19161986)
1. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).
De Clercq E
Biochem Pharmacol; 2009 Jun; 77(11):1655-64. PubMed ID: 19161986
[TBL] [Abstract][Full Text] [Related]
2. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
3. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.
Pusic I; DiPersio JF
Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
5. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.
Cashen AF; Nervi B; DiPersio J
Future Oncol; 2007 Feb; 3(1):19-27. PubMed ID: 17280498
[TBL] [Abstract][Full Text] [Related]
6. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
Devine SM; Flomenberg N; Vesole DH; Liesveld J; Weisdorf D; Badel K; Calandra G; DiPersio JF
J Clin Oncol; 2004 Mar; 22(6):1095-102. PubMed ID: 15020611
[TBL] [Abstract][Full Text] [Related]
7. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
Gazitt Y; Freytes CO; Akay C; Badel K; Calandra G
Stem Cells Dev; 2007 Aug; 16(4):657-66. PubMed ID: 17784839
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
9. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.
Hess DA; Bonde J; Craft TP; Wirthlin L; Hohm S; Lahey R; Todt LM; Dipersio JF; Devine SM; Nolta JA
Biol Blood Marrow Transplant; 2007 Apr; 13(4):398-411. PubMed ID: 17382247
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.
De Clercq E
Mini Rev Med Chem; 2005 Sep; 5(9):805-24. PubMed ID: 16178723
[TBL] [Abstract][Full Text] [Related]
11. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.
Paganessi LA; Walker AL; Tan LL; Holmes I; Rich E; Fung HC; Christopherson KW
Exp Hematol; 2011 Mar; 39(3):384-90. PubMed ID: 21168468
[TBL] [Abstract][Full Text] [Related]
12. Can every patient be mobilized?
DiPersio JF
Best Pract Res Clin Haematol; 2010 Dec; 23(4):519-23. PubMed ID: 21130416
[TBL] [Abstract][Full Text] [Related]
13. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
15. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.
Flomenberg N; DiPersio J; Calandra G
Acta Haematol; 2005; 114(4):198-205. PubMed ID: 16269859
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor (Mozobil).
Med Lett Drugs Ther; 2010 Apr; 52(1335):27-8. PubMed ID: 20360661
[No Abstract] [Full Text] [Related]
17. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
Calandra G; McCarty J; McGuirk J; Tricot G; Crocker SA; Badel K; Grove B; Dye A; Bridger G
Bone Marrow Transplant; 2008 Feb; 41(4):331-8. PubMed ID: 17994119
[TBL] [Abstract][Full Text] [Related]
18. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
De Clercq E
Antivir Chem Chemother; 2019; 27():2040206619829382. PubMed ID: 30776910
[TBL] [Abstract][Full Text] [Related]
19. New agents for mobilizing peripheral blood stem cells.
Greinix HT; Worel N
Transfus Apher Sci; 2009 Aug; 41(1):67-71. PubMed ID: 19615944
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
